



IMMUNOVIA HIGHLIGHTS PANCREASURE PRESENTATION AT INHERITED GASTROINTESTINAL CANCERS MEETING

Immunovia (IMMNOV: Nasdaq Stockholm), the pancreatic cancer diagnostics company, today announced that Dr. Bryson Katona, a key opinion leader, will present at an Immunovia-sponsored symposium during The Collaborative Group of the Americas on Inherited Gastrointestinal Cancer (CGA-IGC) conference. His presentation will highlight the role of blood-based biomarker testing in pancreatic cancer surveillance.

Dr. Bryson Katona, a leading expert on inherited gastrointestinal cancers, will present "*Controversies in Pancreatic Cancer Surveillance Guidelines and the Potential Role for Blood Based Biomarker Testing*", at an Immunovia-sponsored symposium on October 10, 2025.

In his presentation, Dr. Katona, will share the major pancreatic cancer surveillance guidelines and the key differences in recommended patient populations, imaging approaches, and surveillance intervals. He will also highlight the reasons health systems screen high-risk patients differently and how emerging tools like blood-based biomarker testing may influence future pancreatic cancer surveillance.

Bryson Katona, MD, is Associate Professor of Medicine and Genetics at University of Pennsylvania. He is also the Past President of CGA-IGC. As a member of Immunovia's Scientific Advisory Board, Dr. Katona has collaborated on research projects with the company and offers the PancreaSure test at the high-risk surveillance program of University of Pennsylvania.

For further information, please contact

Jeff Borcharding, CEO
jeff.borcharding@immunovia.com

Immunovia in brief

Immunovia AB is a diagnostic company whose mission is to increase survival rates for patients with pancreatic cancer through early detection. Immunovia is focused on the development and commercialization of simple blood-based testing to detect proteins and antibodies that indicate a high-risk individual has developed pancreatic cancer. Immunovia collaborates and engages with healthcare providers, leading experts and patient advocacy groups to make its test available to individuals at increased risk for pancreatic cancer.

USA is the world's largest market for detection of pancreatic cancer. The Company estimates that in the USA, 1.8 million individuals are at high-risk for pancreatic cancer and could benefit from annual surveillance testing.

Immunovia's shares (IMMNOV) are listed on Nasdaq Stockholm.

For more information, please visit www.immunovia.com.